Word

SYNTHORX

Status

Dead

Status Code

606

Status Date

Monday, May 16, 2022

Serial Number

88083193

Mark Type

4000

Filing Date

Friday, August 17, 2018

Published for Opposition

Tuesday, February 12, 2019

Abandoned Date

Monday, May 16, 2022

Trademark Owner History

Synthorx, Inc. - Owner At Publication

Classifications

5 Protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases, and infectious diseases; protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases; protein therapeutics namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, coagulation factors, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, anti-infectives, pain killers, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics

42 Medical research; scientific research in the field of DNA; pharmaceutical research and development; laboratory research services in the field of pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, geriatrics, genetics and phenomics, pathology and forensics, proteomics, and veterinary medicine and diagnostics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents

Trademark Events

May 16, 2022

Abandonment Notice E-Mailed - No Use Statement Filed

May 16, 2022

Abandonment - No Use Statement Filed

Aug 25, 2021

Notice Of Approval Of Extension Request E-Mailed

Aug 24, 2021

Sou Extension 5 Granted

Aug 19, 2021

Sou Extension 5 Filed

Aug 24, 2021

Case Assigned To Intent To Use Paralegal

Aug 19, 2021

Sou Teas Extension Received

Feb 16, 2021

Notice Of Approval Of Extension Request E-Mailed

Feb 12, 2021

Sou Extension 4 Granted

Feb 12, 2021

Sou Extension 4 Filed

Feb 12, 2021

Sou Teas Extension Received

Sep 11, 2020

Notice Of Approval Of Extension Request E-Mailed

Sep 9, 2020

Sou Extension 3 Granted

Sep 9, 2020

Sou Extension 3 Filed

Sep 9, 2020

Sou Teas Extension Received

Apr 1, 2020

Notice Of Approval Of Extension Request E-Mailed

Mar 30, 2020

Sou Extension 2 Granted

Mar 30, 2020

Sou Extension 2 Filed

Mar 30, 2020

Sou Teas Extension Received

Feb 10, 2020

Applicant/Correspondence Changes (Non-Responsive) Entered

Feb 10, 2020

Teas Change Of Owner Address Received

Feb 7, 2020

Attorney/Dom.Rep.Revoked And/Or Appointed

Feb 7, 2020

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Oct 1, 2019

Notice Of Approval Of Extension Request E-Mailed

Sep 27, 2019

Sou Extension 1 Granted

Sep 27, 2019

Sou Extension 1 Filed

Sep 27, 2019

Sou Teas Extension Received

Apr 9, 2019

Noa E-Mailed - Sou Required From Applicant

Feb 12, 2019

Official Gazette Publication Confirmation E-Mailed

Feb 12, 2019

Published For Opposition

Jan 23, 2019

Notification Of Notice Of Publication E-Mailed

Jan 7, 2019

Assigned To Lie

Dec 13, 2018

Approved For Pub - Principal Register

Dec 13, 2018

Examiner's Amendment Entered

Dec 13, 2018

Notification Of Examiners Amendment E-Mailed

Dec 13, 2018

Examiners Amendment E-Mailed

Dec 13, 2018

Examiners Amendment -Written

Dec 13, 2018

Notification Of Non-Final Action E-Mailed

Dec 13, 2018

Non-Final Action E-Mailed

Dec 13, 2018

Non-Final Action Written

Dec 4, 2018

Assigned To Examiner

Aug 27, 2018

New Application Office Supplied Data Entered

Aug 21, 2018

New Application Entered